IFNL4 rs12979861: What Your Genotype Means
The rs12979861 variant is a genetic marker located within the IFNL4 gene region. It is widely studied for its statistical association with the body's ability to spontaneously clear Hepatitis C virus (HCV) infections and respond to interferon-based treatments.
What each genotype means
Reduced viral clearance potential
This genotype is associated with a lower likelihood of spontaneously clearing Hepatitis C virus (HCV) infection compared to other genotypes. Research indicates this variant influences the IFNL4 gene, which plays a role in the body's antiviral response. Please discuss any concerns regarding viral infection management or treatment response with your clinician.
This genotype is common in many populations, though its frequency varies significantly by ancestry.
Intermediate viral clearance potential
This genotype represents a heterozygous state that may result in an intermediate response regarding the body's ability to clear certain viral infections like Hepatitis C. Because this variant affects the function of the IFNL4 gene, it is often studied in the context of how individuals respond to antiviral therapies. You should consult with your healthcare provider to understand how this may relate to your specific health profile.
This genotype is frequently observed across diverse global populations.
Enhanced viral clearance potential
This genotype is associated with a higher likelihood of spontaneous clearance of Hepatitis C virus (HCV) infection and often correlates with a more favorable response to certain interferon-based antiviral treatments. The TT genotype is linked to the functional inactivation of the IFNL4 protein, which paradoxically improves the body's ability to clear the virus. Please discuss any questions about your health or treatment options with your doctor.
This genotype is common in many populations, with a 10-fold difference in frequency observed across different ancestral groups.
Understanding the Variant and Its Location
The rs12979861 variant is a single nucleotide polymorphism (SNP) situated in the intronic region of the IFNL4 gene on chromosome 19. While it is often discussed in the context of the neighboring IFNL3 gene (historically referred to as IL28B), research has clarified that this variant is functionally linked to the expression of the IFNL4 protein. The variant acts as a genetic tag, meaning it is inherited alongside other nearby genetic changes that directly influence how the body produces interferon lambda 4. Because these variants are in strong linkage disequilibrium, rs12979861 serves as a reliable proxy for identifying individuals who may have different biological responses to certain viral infections. It is important to note that this variant does not cause disease itself, but rather represents a variation in the immune system's regulatory landscape.
The Role of the IFNL4 Gene
The IFNL4 gene encodes a cytokine called interferon lambda 4, which is part of the body's innate immune response to viral infections. Interestingly, the presence of certain alleles at this locus can lead to the production of a functional protein, while other alleles prevent its expression. Paradoxically, research has shown that the absence of the IFNL4 protein is often associated with better outcomes in clearing the Hepatitis C virus. Scientists believe this occurs because the protein, when produced, may induce cellular stress that interferes with the immune system's ability to effectively present viral antigens to T cells. By understanding how this gene functions, researchers have gained deeper insights into why some individuals naturally clear viral infections while others develop chronic conditions. This biological mechanism highlights the complex balance between immune activation and viral persistence.
Research Associations and Evidence Strength
The association between IFNL4 variants and Hepatitis C clearance is one of the most well-replicated findings in viral genomics. Numerous studies have demonstrated that individuals with specific genotypes at this locus are significantly more likely to achieve spontaneous clearance of HCV and show improved responses to interferon-based therapies. However, the evidence strength is considered limited in terms of clinical utility for modern direct-acting antiviral (DAA) treatments, which have largely replaced older interferon-based regimens. Furthermore, while some studies have explored potential links between IFNL4 variants and other RNA viruses, such as SARS-CoV-2, these findings are still evolving and require further validation. It is crucial to recognize that these associations are statistical in nature and do not account for all factors influencing infection outcomes, such as viral load, overall health, and environmental exposures.
Population Frequency and Diversity
The frequency of the rs12979861 alleles varies significantly across different ancestral populations, which is a critical consideration in genetic research. In European populations, the minor allele frequency (MAF) is approximately 0.30, whereas in East Asian populations, the frequency is notably higher, often exceeding 0.60. These differences underscore the importance of studying genetic variants across diverse groups to ensure that findings are applicable globally. Because linkage disequilibrium patterns can differ between ancestries, a variant that serves as a strong marker in one population may not have the same predictive power in another. Researchers continue to analyze these frequency distributions to better understand the evolutionary history of the IFNL4 region and its impact on human health across different geographic regions.
What This Information Means for You
Knowing your genotype for rs12979861 provides insight into your genetic predisposition regarding specific viral clearance patterns, but it is not a diagnostic tool. This information cannot predict your personal health outcome or guarantee how you will respond to any specific medical treatment. If you are concerned about Hepatitis C or any other viral infection, it is essential to consult with a healthcare professional or a specialist. They can provide appropriate testing, interpret your results in the context of your full medical history, and discuss the most effective, evidence-based treatment options available today. Never make decisions about your health or medication based solely on genetic data. Always discuss any questions regarding your health, potential risks, or treatment plans with your clinician or pharmacist to ensure you receive personalized and accurate medical guidance.
How common is this variant?
The rs12979861 variant shows significant ancestral variation, with a minor allele frequency of approximately 0.30 in Europeans and over 0.60 in East Asian populations.
Frequently asked questions
Is rs12979861 a test for Hepatitis C?
No, rs12979861 is not a diagnostic test for Hepatitis C. It is a genetic marker that may be associated with how your body responds to the virus, but it cannot tell you if you are currently infected.
Does my genotype mean I will definitely clear a virus?
No, genetic associations are statistical probabilities, not certainties. Many factors, including your overall health and the specific type of virus, play a much larger role in your body's ability to clear an infection.
Should I change my medication based on this SNP?
You should never change your medication based on genetic information alone. Always discuss your treatment plan and any genetic test results with your clinician or pharmacist.
Why is this variant sometimes called IL28B?
The variant was historically associated with the IL28B gene (now known as IFNL3). Later research clarified that the functional effects are actually driven by the nearby IFNL4 gene.
Sources & further reading
Educational information only, last refreshed 9/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12979861?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IFNL4
Variant in the IFNL4 region associated with spontaneous clearance of hepatitis C virus and response to interferon therapy.
Located in the IFNL4/IFNL3 region, this variant strongly predicted pegylated-interferon/ribavirin efficacy, though direct-acting antiviral (DAA) regimens have largely superseded its standard clinical utility.